Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo

[1]  J. Lorberbaum,et al.  Neural correlates of speech anticipatory anxiety in generalized social phobia , 2004, Neuroreport.

[2]  Claude Nahmias,et al.  A PET provocation study of generalized social phobia , 2004, Psychiatry Research: Neuroimaging.

[3]  Mats Fredrikson,et al.  Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia , 2004, Neuroscience Letters.

[4]  S. Preskorn,et al.  Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression , 2004, Neuropsychopharmacology.

[5]  G. Klerman,et al.  Assessing impairment in patients with panic disorder: the Sheehan Disability Scale , 1992, Social Psychiatry and Psychiatric Epidemiology.

[6]  G. Bentley,et al.  Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608 , 2003, Neuropharmacology.

[7]  M. Liebowitz,et al.  Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder , 2003, Psychological Medicine.

[8]  R. Adolphs.  Cognitive neuroscience: Cognitive neuroscience of human social behaviour , 2003, Nature Reviews Neuroscience.

[9]  T. Furmark,et al.  Cerebral blood flow during anticipation of public speaking in social phobia: a PET study , 2002, Biological Psychiatry.

[10]  M. Raichle,et al.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.

[11]  J. Gorman,et al.  Molecular targets in the treatment of anxiety , 2002, Biological Psychiatry.

[12]  Gregory G. Brown,et al.  Increased amygdala activation to angry and contemptuous faces in generalized social phobia. , 2002, Archives of general psychiatry.

[13]  R. V. Van Heertum,et al.  Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652 , 2002, Psychopharmacology.

[14]  J. Lachowicz,et al.  The Gerbil Elevated Plus-maze II: Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists , 2002, Neuropsychopharmacology.

[15]  Michael Erb,et al.  Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans , 2002, Neuroscience Letters.

[16]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[17]  F. Graeff.  On serotonin and experimental anxiety , 2002, Psychopharmacology.

[18]  S. Hofmann,et al.  The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. , 2002, Behaviour research and therapy.

[19]  D. Clark,et al.  Patients with generalized social phobia direct their attention away from faces. , 2002, Behaviour research and therapy.

[20]  R. L. Ribeiro,et al.  Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  T. Furmark,et al.  Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. , 2002, Archives of general psychiatry.

[22]  T. Furmark,et al.  Social phobia: overview of community surveys , 2002, Acta psychiatrica Scandinavica.

[23]  David G. Amaral,et al.  The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety , 2002, Biological Psychiatry.

[24]  Dan J Stein,et al.  Functional brain imaging and pharmacotherapy in trichotillomania Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  R. Gomeni,et al.  Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. , 2002, Nuclear medicine and biology.

[26]  M. Mintun,et al.  Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study , 2001, Biological Psychiatry.

[27]  H Fischer,et al.  Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. , 2001, The American journal of psychiatry.

[28]  I. Holme,et al.  Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia , 2001, British Journal of Psychiatry.

[29]  M. Keller,et al.  An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. , 2001, Psychiatric services.

[30]  R. Hen,et al.  Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Michael Davis,et al.  The amygdala: vigilance and emotion , 2001, Molecular Psychiatry.

[32]  Joseph E LeDoux.  Emotion circuits in the brain. , 2009, Annual review of neuroscience.

[33]  D. Nutt,et al.  The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology. , 2000, Pharmacology & therapeutics.

[34]  N. Kalin,et al.  Emotion, plasticity, context, and regulation: perspectives from affective neuroscience. , 2000, Psychological bulletin.

[35]  P. Jerabek,et al.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.

[36]  R. Schwarting,et al.  Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery , 2000, Neuropeptides.

[37]  P. Farvolden,et al.  Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI , 2000, Expert opinion on investigational drugs.

[38]  S. Stahl,et al.  Serotonin and anxiety: current models , 2000, International clinical psychopharmacology.

[39]  S. File.  NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats , 2000, Psychopharmacology.

[40]  J L Lancaster,et al.  Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.

[41]  Dan J Stein,et al.  Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[42]  J M Gorman,et al.  Neuroanatomical hypothesis of panic disorder, revised. , 2000, The American journal of psychiatry.

[43]  M. Liebowitz,et al.  Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study , 1999, European Psychiatry.

[44]  Dan J Stein,et al.  Social anxiety disorder , 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[45]  M S Kramer,et al.  Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.

[46]  T. Furmark,et al.  Social phobia in the general population: prevalence and sociodemographic profile , 1999, Social Psychiatry and Psychiatric Epidemiology.

[47]  R. Maddock.  The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain , 1999, Trends in Neurosciences.

[48]  P. Farvolden,et al.  Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia , 1999 .

[49]  G. Griebel,et al.  Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? , 1999, Pharmacology & therapeutics.

[50]  Wolfgang Grodd,et al.  Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia , 1999, Biological Psychiatry.

[51]  B. Lerer,et al.  Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers , 1999, Psychopharmacology.

[52]  J. Gorman,et al.  SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. , 1999, The Journal of clinical psychiatry.

[53]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[54]  U Klose,et al.  fMRI reveals amygdala activation to human faces in social phobics , 1998, Neuroreport.

[55]  S. Paradiso.  The Emotional Brain: The Mysterious Underpinnings of Emotional Life , 1998 .

[56]  R. Mattick,et al.  Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. , 1998, Behaviour research and therapy.

[57]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[58]  J. Davidson.  Pharmacotherapy of social anxiety disorder. , 1998, The Journal of clinical psychiatry.

[59]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[60]  S. File.  Anxiolytic Action of a Neurokinin1 Receptor Antagonist in the Social Interaction Test , 1997, Pharmacology Biochemistry and Behavior.

[61]  E. Courchesne,et al.  Attentional Activation of the Cerebellum Independent of Motor Involvement , 1997, Science.

[62]  E. Hollander,et al.  The neuroanatomy of 5-HT dysregulation and panic disorder. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[63]  Kiyohisa Takahashi,et al.  Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat , 1996, Brain Research.

[64]  M. Brandão,et al.  Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test , 1996, Physiology & Behavior.

[65]  J. Calixto,et al.  Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. , 1996, European journal of pharmacology.

[66]  Daniel S. O'Leary,et al.  Sample Size and Statistical Power in [15O]H2O Studies of Human Cognition , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[67]  Gavin Kilpatrick,et al.  GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity , 1996, Regulatory Peptides.

[68]  Joseph E LeDoux.  The emotional brain , 1996 .

[69]  J. Gray,et al.  The neuropsychology of anxiety: reprise. , 1996, Nebraska Symposium on Motivation. Nebraska Symposium on Motivation.

[70]  E. Lindström,et al.  Axis V—Global Assessment of Functioning Scale , 1994, Acta psychiatrica Scandinavica.

[71]  M. Koch,et al.  Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats , 1994, Behavioural Brain Research.

[72]  E. Brodin,et al.  Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions , 1994, Neuropeptides.

[73]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[74]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[75]  A. Ganong,et al.  Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. , 1991, Science.

[76]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[77]  Lars R. Bergman,et al.  EXACON: A Fortran 77 Program for the Exact Analysis of Single Cells in a Contingency Table , 1987 .

[78]  J. Gray,et al.  The neuropsychology of anxiety. , 1985, Issues in mental health nursing.

[79]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .

[80]  R. Hunter.  Insight vs. Desensitization in Psychotherapy , 1966 .